Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 56

1.

USP1 links platinum resistance to cancer cell dissemination by regulating Snail stability.

Sonego M, Pellarin I, Costa A, Vinciguerra GLR, Coan M, Kraut A, D'Andrea S, Dall'Acqua A, Castillo-Tong DC, Califano D, Losito S, Spizzo R, Couté Y, Vecchione A, Belletti B, Schiappacassi M, Baldassarre G.

Sci Adv. 2019 May 8;5(5):eaav3235. doi: 10.1126/sciadv.aav3235. eCollection 2019 May.

2.

Retraction: FRA-1 Expression in Hyperplastic and Neoplastic Thyroid Diseases.

Chiappetta G, Tallini G, De Biasio MC, Pentimalli F, de Nigris F, Losito S, Fedele M, Battista S, Verde P, Santoro M, Fusco A.

Clin Cancer Res. 2019 Apr 15;25(8):2675. doi: 10.1158/1078-0432.CCR-19-0487. No abstract available.

PMID:
30988099
3.

The MITO CERV-2 trial: A randomized phase II study of cetuximab plus carboplatin and paclitaxel, in advanced or recurrent cervical cancer.

Pignata S, Scambia G, Lorusso D, De Giorgi U, Nicoletto MO, Lauria R, Mosconi AM, Sacco C, Omarini C, Tagliaferri P, Ferrandina G, Cinieri S, Savarese A, Valabrega G, Pisano C, Salutari V, Raspagliesi F, Kopf B, Cecere SC, Amadio G, Maltese G, Di Napoli M, Greggi S, Signoriello S, Daniele G, Sacco A, Losito S, Normanno N, Perrone F, Gallo C, Piccirillo MC; MITO Investigators.

Gynecol Oncol. 2019 Jun;153(3):535-540. doi: 10.1016/j.ygyno.2019.03.260. Epub 2019 Apr 9.

PMID:
30979589
4.

Angiosarcoma and anaplastic carcinoma of the thyroid are two distinct entities: a morphologic, immunohistochemical, and genetic study.

Kuhn E, Ragazzi M, Ciarrocchi A, Torricelli F, de Biase D, Zanetti E, Bisagni A, Corrado S, Uccella S, La Rosa S, Bongiovanni M, Losito S, Piana S.

Mod Pathol. 2019 Jun;32(6):787-798. doi: 10.1038/s41379-018-0199-z. Epub 2019 Feb 5.

PMID:
30723294
5.

Prevalence of "unclassified" HPV genotypes among women with abnormal cytology.

Annunziata C, Stellato G, Greggi S, Sanna V, Curcio MP, Losito S, Botti G, Buonaguro L, Buonaguro FM, Tornesello ML.

Infect Agent Cancer. 2018 Jul 24;13:26. doi: 10.1186/s13027-018-0199-0. eCollection 2018.

6.

Distinct profiles of TERT promoter mutations and telomerase expression in head and neck cancer and cervical carcinoma.

Annunziata C, Pezzuto F, Greggi S, Ionna F, Losito S, Botti G, Buonaguro L, Buonaguro FM, Tornesello ML.

Int J Cancer. 2018 Sep 1;143(5):1153-1161. doi: 10.1002/ijc.31412. Epub 2018 Apr 17.

PMID:
29603728
7.

Immunotherapy in ovarian, endometrial and cervical cancer: State of the art and future perspectives.

Ventriglia J, Paciolla I, Pisano C, Cecere SC, Di Napoli M, Tambaro R, Califano D, Losito S, Scognamiglio G, Setola SV, Arenare L, Pignata S, Della Pepa C.

Cancer Treat Rev. 2017 Sep;59:109-116. doi: 10.1016/j.ctrv.2017.07.008. Epub 2017 Jul 31. Review.

PMID:
28800469
8.

Hashimoto's thyroiditis predicts outcome in intrathyroidal papillary thyroid cancer.

Marotta V, Sciammarella C, Chiofalo MG, Gambardella C, Bellevicine C, Grasso M, Conzo G, Docimo G, Botti G, Losito S, Troncone G, De Palma M, Giacomelli L, Pezzullo L, Colao A, Faggiano A.

Endocr Relat Cancer. 2017 Sep;24(9):485-493. doi: 10.1530/ERC-17-0085. Epub 2017 Jul 10.

PMID:
28696209
9.

Comparative analysis of HPV16 gene expression profiles in cervical and in oropharyngeal squamous cell carcinoma.

Cerasuolo A, Annunziata C, Tortora M, Starita N, Stellato G, Greggi S, Maglione MG, Ionna F, Losito S, Botti G, Buonaguro L, Buonaguro FM, Tornesello ML.

Oncotarget. 2017 May 23;8(21):34070-34081. doi: 10.18632/oncotarget.15977.

10.

Germline Polymorphisms of the VEGF Pathway Predict Recurrence in Nonadvanced Differentiated Thyroid Cancer.

Marotta V, Sciammarella C, Capasso M, Testori A, Pivonello C, Chiofalo MG, Gambardella C, Grasso M, Antonino A, Annunziata A, Macchia PE, Pivonello R, Santini L, Botti G, Losito S, Pezzullo L, Colao A, Faggiano A.

J Clin Endocrinol Metab. 2017 Feb 1;102(2):661-671. doi: 10.1210/jc.2016-2555.

PMID:
27849428
11.

Long-Term Oncologic and Reproductive Outcomes in Young Women With Early Endometrial Cancer Conservatively Treated: A Prospective Study and Literature Update.

Laurelli G, Falcone F, Gallo MS, Scala F, Losito S, Granata V, Cascella M, Greggi S.

Int J Gynecol Cancer. 2016 Nov;26(9):1650-1657.

PMID:
27654262
12.

Fertility preserving treatment with hysteroscopic resection followed by progestin therapy in young women with early endometrial cancer.

Falcone F, Laurelli G, Losito S, Di Napoli M, Granata V, Greggi S.

J Gynecol Oncol. 2017 Jan;28(1):e2. doi: 10.3802/jgo.2017.28.e2. Epub 2016 Aug 8.

13.

Biomarker analysis of the MITO2 phase III trial of first-line treatment in ovarian cancer: predictive value of DNA-PK and phosphorylated ACC.

Perrone F, Baldassarre G, Indraccolo S, Signoriello S, Chiappetta G, Esposito F, Ferrandina G, Franco R, Mezzanzanica D, Sonego M, Zulato E, Zannoni GF, Canzonieri V, Scambia G, Sorio R, Savarese A, Breda E, Scollo P, Ferro A, Tamberi S, Febbraro A, Natale D, Di Maio M, Califano D, Scognamiglio G, Lorusso D, Canevari S, Losito S, Gallo C, Pignata S.

Oncotarget. 2016 Nov 8;7(45):72654-72661. doi: 10.18632/oncotarget.12056.

14.

Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study.

Bagnoli M, Canevari S, Califano D, Losito S, Maio MD, Raspagliesi F, Carcangiu ML, Toffoli G, Cecchin E, Sorio R, Canzonieri V, Russo D, Scognamiglio G, Chiappetta G, Baldassarre G, Lorusso D, Scambia G, Zannoni GF, Savarese A, Carosi M, Scollo P, Breda E, Murgia V, Perrone F, Pignata S, De Cecco L, Mezzanzanica D; Multicentre Italian Trials in Ovarian cancer (MITO) translational group.

Lancet Oncol. 2016 Aug;17(8):1137-1146. doi: 10.1016/S1470-2045(16)30108-5. Epub 2016 Jul 9.

15.

Detection of human papillomavirus DNA in peri-tumor tissues and pelvic lymph nodes as potential molecular marker of micrometastasis in cervical cancer.

Tortora M, Annunziata C, Liguori G, Losito S, Botti G, Greggi S, Buonaguro L, Buonaguro FM, Tornesello ML.

Infect Agent Cancer. 2016 May 11;11:22. doi: 10.1186/s13027-016-0068-7. eCollection 2016.

16.

Fertility-sparing management of low-grade endometrial stromal sarcoma: analysis of an institutional series and review of the literature.

Laurelli G, Falcone F, Scaffa C, Messalli EM, Del Giudice M, Losito S, Greggi S.

Eur J Obstet Gynecol Reprod Biol. 2015 Dec;195:61-6. doi: 10.1016/j.ejogrb.2015.09.041. Epub 2015 Oct 8. Review.

PMID:
26476800
17.

PATZ1 acts as a tumor suppressor in thyroid cancer via targeting p53-dependent genes involved in EMT and cell migration.

Chiappetta G, Valentino T, Vitiello M, Pasquinelli R, Monaco M, Palma G, Sepe R, Luciano A, Pallante P, Palmieri D, Aiello C, Rea D, Losito SN, Arra C, Fusco A, Fedele M.

Oncotarget. 2015 Mar 10;6(7):5310-23.

18.

Clear cell myoepithelial carcinoma of salivary glands showing EWSR1 rearrangement: molecular analysis of 94 salivary gland carcinomas with prominent clear cell component.

Skálová A, Weinreb I, Hyrcza M, Simpson RH, Laco J, Agaimy A, Vazmitel M, Majewska H, Vanecek T, Talarčik P, Manajlovic S, Losito SN, Šteiner P, Klimkova A, Michal M.

Am J Surg Pathol. 2015 Mar;39(3):338-48. doi: 10.1097/PAS.0000000000000364.

PMID:
25581728
19.

Low Grade Serous Ovarian Carcinoma: from the molecular characterization to the best therapeutic strategy.

Della Pepa C, Tonini G, Santini D, Losito S, Pisano C, Di Napoli M, Cecere SC, Gargiulo P, Pignata S.

Cancer Treat Rev. 2015 Feb;41(2):136-43. doi: 10.1016/j.ctrv.2014.12.003. Epub 2014 Dec 23. Review.

PMID:
25573350
20.

CXCR4 expression affects overall survival of HCC patients whereas CXCR7 expression does not.

Neve Polimeno M, Ierano C, D'Alterio C, Simona Losito N, Napolitano M, Portella L, Scognamiglio G, Tatangelo F, Maria Trotta A, Curley S, Costantini S, Liuzzi R, Izzo F, Scala S.

Cell Mol Immunol. 2015 Jul;12(4):474-82. doi: 10.1038/cmi.2014.102. Epub 2014 Nov 3.

Supplemental Content

Loading ...
Support Center